BCAB vs. CRDF, SCLX, CRDL, MOLN, VCXB, VXRT, DBVT, CLLS, GNFT, and VIGL
Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Cardiff Oncology (CRDF), Scilex (SCLX), Cardiol Therapeutics (CRDL), Molecular Partners (MOLN), 10X Capital Venture Acquisition Corp. III (VCXB), Vaxart (VXRT), DBV Technologies (DBVT), Cellectis (CLLS), Genfit (GNFT), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.
Cardiff Oncology (NASDAQ:CRDF) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.
Cardiff Oncology has higher revenue and earnings than BioAtla. Cardiff Oncology is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 6.3% of Cardiff Oncology shares are owned by company insiders. Comparatively, 11.5% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cardiff Oncology presently has a consensus target price of $10.50, suggesting a potential upside of 228.13%. BioAtla has a consensus target price of $11.00, suggesting a potential upside of 251.44%. Given Cardiff Oncology's higher probable upside, analysts plainly believe BioAtla is more favorable than Cardiff Oncology.
In the previous week, Cardiff Oncology had 3 more articles in the media than BioAtla. MarketBeat recorded 10 mentions for Cardiff Oncology and 7 mentions for BioAtla. Cardiff Oncology's average media sentiment score of 0.32 beat BioAtla's score of 0.27 indicating that BioAtla is being referred to more favorably in the news media.
Cardiff Oncology has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
Cardiff Oncology received 16 more outperform votes than BioAtla when rated by MarketBeat users. However, 66.67% of users gave BioAtla an outperform vote while only 62.30% of users gave Cardiff Oncology an outperform vote.
BioAtla has a net margin of 0.00% compared to BioAtla's net margin of -6,594.92%. BioAtla's return on equity of -54.54% beat Cardiff Oncology's return on equity.
Summary
BioAtla beats Cardiff Oncology on 9 of the 17 factors compared between the two stocks.
Get BioAtla News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
